Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Medicxi
Deal Size : $21.1 million
Deal Type : Series A Financing
French Biotech Raises €19M to Hit Phase I with Cancer Immunotherapy
Details : The Series A round of funding from Advent France Biotechnology and Medicxi will be used to complete the preclinical development of its regulatory T cell depleting CD25-specific antibody.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 01, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Medicxi
Deal Size : $21.1 million
Deal Type : Series A Financing